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Abstract
Advancements towards an improved vaccine against Bacillus anthracis, the causative agent of
anthrax, have focused on formulations composed of the protective antigen (PA) adsorbed to
aluminum hydroxide. However, due to the labile nature of PA, antigen stability is a primary
concern for vaccine development. Thus, there is a need for a delivery system capable of preserving
the immunogenicity of PA through all the steps of vaccine fabrication, storage, and administration.
In this work, we demonstrate that biodegradable amphiphilic polyanhydride nanoparticles, which
have previously been shown to provide controlled antigen delivery, antigen stability, immune
modulation, and protection in a single dose against a pathogenic challenge, can stabilize and
release functional PA. These nanoparticles demonstrated polymer hydrophobicity-dependent
preservation of the biological function of PA upon encapsulation, storage (over extended times
and elevated temperatures), and release. Specifically, fabrication of amphiphilic polyanhydride
nanoparticles composed of 1,6-bis(p-carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane best preserved PA functionality. These studies demonstrate the versatility and
superiority of amphiphilic nanoparticles as vaccine delivery vehicles suitable for long-term
storage.
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Introduction
Anthrax is a significant public health concern due to its potential as a bioterrorism and
biowarfare agent. Use of the currently licensed alum-adjuvanted anthrax vaccine adsorbed
(AVA) poses many concerns due to its high reactogenicity, multi-dose (five) immunization
schedule followed by yearly boosters, and painful side effects1. The recombinant protective
antigen (PA) from Bacillus anthracis, the key element of the AVA vaccine that confers
immunity against an anthrax infection, has been the focus for new vaccines2. PA is the
receptor-binding subunit for both lethal factor (LF) and edema factor (EF), which upon
binding, lead to the formation of lethal toxin (LT) and edema toxin (ET), respectively3.
Although highly immunogenic, PA is unfortunately a labile recombinant protein, especially
in low pH and high temperature environments4–7. These stability concerns have led to
manufacturing roadblocks during a Phase I clinical trial for a new anthrax vaccine based on
PA8.
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In addition to stability concerns during the vaccine manufacturing process, there are other
obstacles for PA-based vaccines. PA circulating in the blood stream is eliminated within six
hours;3, 9 this limited in vivo half-life may fail to induce a protective immune response.
Studies by Zinkernagel and others have shown that antigen persistence is a key element
associated with the development of a protective immune response10, 11. Several methods
have been employed to increase PA availability to the immune system and improve its
immunogenicity, including engineering recombinant PA, incorporating other antigens or
adjuvants in the vaccine, evaluating alternate delivery routes, and using controlled delivery
systems3. Currently, the AVA vaccine is administered intramuscularly and many murine
studies have focused on subcutaneous delivery of PA. As an alternative, intranasal
vaccination has been reported as the best route for induction of a protective immune
response3, 12. While PA is a relatively good immunogen, it may be essential to use an
adjuvant; however, well known mucosal adjuvants (e.g., cholera, pertussis, and edema
toxins and CpG DNA) have limitations due to their potential toxicity when delivered by this
route in humans3, 13.
This work focuses on the development and refinement of a controlled delivery system for
PA based on biodegradable polyanhydride nanoparticles. Polyanhydrides are a class of
biomaterials with excellent biocompatibility and have been extensively studied as vaccine
delivery vehicles and adjuvants14–19. These polymer formulations provide safe parenteral
delivery20, enhanced adjuvanticity16, 17, 21, sustained release of encapsulated antigens22–28,
and a stabilizing environment for protein antigens during fabrication, storage, and
release22–26, 28–30. Specifically, micro- and nanoparticles made of copolymers based upon
sebacic anhydride (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) are suitable for inhalation or injection.
Moreover, they possess tunable antigen release kinetics22–28, 30 that provide an in vivo
antigen depot, thereby allowing for sustained antigen exposure and eliminating the need for
multiple administrations. These surface eroding polymers slowly release encapsulated
antigen, minimizing exposure to unfavorable aqueous environments.
The overall goal of this work was to design nanoparticle-based formulations capable of
encapsulating and releasing biologically functional PA that results in a robust, high avidity,
neutralizing antibody response after a single administration. In this regard, nanoparticles
based on 50:50 CPTEG:CPH, 20:80 CPTEG:CPH, 50:50 CPH:SA, and 20:80 CPH:SA were
investigated for their ability to stabilize and release biologically active and immunogenic
PA. In contrast to CPH:SA nanoparticles, amphiphilic CPTEG:CPH nanoparticles better
preserved the functionality and immunogenicity of PA during nanoparticle fabrication,
storage, and release. The use of amphiphilic polyanhydride nanoparticles as delivery
vehicles presents a viable solution for long-term vaccine storage.
Experimental Section
Materials
Chemicals needed for polymerization, nanoparticle fabrication, and buffer preparation
included acetic anhydride, chloroform, methylene chloride, petroleum ether, pentane,
monobasic potassium phosphate, and dibasic potassium phosphate; all were purchased from
Fisher Scientific (Fairlawn, NJ). Monomer synthesis utilized the following chemicals: 1,6-
dibromohexane, tri-ethylene glycol, 4-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone;
these were purchased from Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was
purchased from Apollo Scientific (Cheshire, UK); and sulfuric acid, acetonitrile, dimethyl
formamide, toluene, and potassium carbonate were obtained from Fisher Scientific.
Deuterated chemicals for NMR (nuclear magnetic resonance) analysis, chloroform and
dimethyl sulfoxide were purchased from Cambridge Isotope Laboratories (Andover, MA).
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Polymer synthesis, nanoparticle fabrication, protein encapsulation, and characterization
The CPH and CPTEG monomers were synthesized as described previously31, 32. The SA
monomer was purchased from Sigma Aldrich (St. Louis, MO). Pre-polymer and polymers
were synthesized as described before28, 33. The CPTEG:CPH and CPH:SA copolymers were
formed into nanoparticles as described previously17, 27, 29. Briefly, PA (NIH Biodefense and
Emerging Infections Research Resources Repository, Manassas, VA) loaded nanoparticles
(2% (w/w)) were fabricated by dissolving the desired polymer in methylene chloride at a
concentration of 25 mg/mL. The desired amount of lyophilized PA was added to the
dissolved polymer, the solution sonicated (40 Hz for 30 s), poured into a non-solvent
(pentane) at a solvent to non-solvent ratio of 1 to 200, and then vacuum filtered to recover
the PA-loaded nanoparticles (20–150 mg batch size). Polymer molecular mass, chemical
structure, and chemical composition were determined with 1H NMR spectroscopy using a
Varian VXR 300 MHz spectrometer (Varian Inc., Palo Alto, CA). Specifically, the
molecular mass was determined by end group analysis of NMR spectra. Nanoparticle size
and morphology were characterized with scanning electron microscopy (SEM; JEOL 840 A,
JEOL Peabody, MA).
In vitro protein release kinetics
PA-loaded nanoparticles at a concentration of approximately 50 mg/mL were incubated with
0.1 M PBS buffer (pH 7.4) in capped microcentrifuge tubes. Samples were sonicated to
ensure uniform nanoparticle distribution and placed in a shaker/incubator at 37°C. Sample
supernatants were removed (entire volume) incrementally to measure the amount of released
PA (PArel), which was analyzed using a micro-bicinchoninic acid (BCA) assay. Once
supernatants were removed, equivalent volumes of PBS buffer were added back to maintain
perfect sink conditions. Data is presented as cumulative percentage of PA released, which
was determined by normalizing the cumulative amount released at each time point by the
total amount encapsulated into the nanoparticles22–28, 30.
In vitro pH change upon nanoparticle degradation
Blank nanoparticles at a concentration of approximately 100 mg/mL were incubated with
0.1 M PBS buffer (pH 7.6) in microcentrifuge tubes. Samples were sonicated to ensure
uniform nanoparticle distribution and placed in a shaker/incubator at 37°C. The pH
measurements were carried out at various time points with a pH probe to monitor the
buildup of acidic degradation products.
In vitro release of PA for analysis of bioactivity, antigenicity, and structure
Treatment groups tested for their effect on PA stability were 20:80 CPTEG:CPH, 50:50
CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA nanoparticles, native PA (i.e., positive
control stored at −20°C), and protein exposed to nanoparticle fabrication conditions (NFC)
which included sonication (40 Hz for 30 s), solvent exposure (methylene chloride and
pentane), and vacuum drying. All groups were sonicated and incubated with 0.1 M PBS
buffer (pH 7.4) in microcentrifuge tubes in a shaker/incubator at 37°C. In order to
accumulate enough of the PArel for characterization, PA-loaded nanoparticles were
incubated for two days. Following release, supernatants were removed and the
concentration, antigenicity, bioactivity, and structural alterations of the PArel were assessed.
Circular dichroism: secondary structure
Far UV circular dichroism (CD) (190–250 nm) was used to study the changes in protein
secondary structure of the PArel. All CD spectra were collected for samples on a Jasco J-170
Spectropolarimeter (Easton, MD). The emission spectrum from 200–260 nm was analyzed
for shifts in molar ellipticity and wavelength, which are indicative of alterations in protein
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secondary structure. The experiments were performed in triplicate using a 200 μL sample
volume.
Fluorescence spectroscopy: tertiary structure
Fluorescence spectroscopy was used to study the changes in tertiary structure of the PArel
with a Cary Eclipse fluorescence spectrometer (Varian, Inc., Palo Alto, CA). Samples were
excited at a wavelength of 280 nm and a voltage of 800 V, which resulted in an emission
spectrum that corresponds to the tryptophan and tyrosine residues of the protein. The
emission spectrum from 300–500 nm was analyzed for shifts in peak intensity and
wavelength that are indicative of alterations in protein tertiary structure. The experiments
were performed in triplicate.
In vitro release of PA for in vivo administration of the PArel
PA-loaded nanoparticle (2% w/w) samples (200 mg) were incubated in 0.1 M PBS (pH 7.4)
for 14 days at 4°C in dialysis cassettes (4,000 Da MWCO) to accumulate enough of the
PArel for immunization. This release was carried out at 4°C to prevent temperature induced
instability. Protein concentration was determined with a micro-BCA assay and all samples
were adjusted to a final concentration of 200 μg/mL. Equal amounts of PA released from
20:80 CPTEG:CPH, 50:50 CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA nanoparticles
and native PA were adsorbed to Imject Alum (Fisher Scientific). A/J mice (Jackson
Laboratories, Bar Harbor, Maine) were immunized subcutaneously in the nape of the neck
with a dose of 10 μg of the PArel or native PA (3 or 4 mice per group). Each mouse was
given a second immunization on day 15 with 10 μg of the PArel or native PA corresponding
to the primary immunization regimen, euthanized on day 21, and serum collected. All
animal procedures were conducted with the approval of the Iowa State University
Institutional Animal Care and Use Committee.
Enzyme-linked immunosorbent assay (ELISA): PA-specific serum antibody response
PA-specific serum antibody response (total IgG [H+L]) and PArel antigenicity were
analyzed via ELISA using a previously described method with modifications19. High-
binding 96 well ELISA plates (Fisher Scientific) were coated in PBS buffer (pH 7.2, 0.05M)
with 0.5 μg/mL native PA or PArel overnight at 4°C. After washing with buffer (PBS
containing 0.5% Tween 20 (PBS-T)), plates were blocked for 2 h (PBS containing 0.5 %
Tween 20 (PBS-T) and 2% gelatin) at room temperature, washed three times in PBS-T, and
incubated with mouse serum (from individual mice, not pooled) for 24 h at dilutions from
1:1,000 to 1:1,000,000 overnight at 4°C. The following day, plates were washed three times
in PBS-T, incubated with alkaline phosphatase-conjugated goat anti- IgG [H+L] antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 h at room temperature,
washed again, and incubated with alkaline phosphatase substrate buffer (Sigma Aldrich) for
2 h at room temperature. Absorbance was measured at an optical density (OD) of 405 nm
using a Spectramax 190 Plate Reader (Molecular Devices, Sunnyvale, CA). Each sample
was analyzed in triplicate.
ELISA for serum antibody avidity
Serum antibody avidity was determined by modifying an ELISA method described
previously19. The avidity assay was performed similarly to the serum antibody response
protocol described above. Following serum incubation for 24 h at a dilution of 1:1,000,000,
the chaotropic agent, sodium thiocyanate, was added to the wells using incremental
increases over a concentration range from 0 to 5 M. Plates were incubated for 20 min at
room temperature and then washed four times in PBS-T. The detection of bound serum
antibody was performed as described above. Relative avidity index is defined as the
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concentration of sodium thiocyanate required to decrease the optical density by 50% of that
obtained for each control well (i.e., no sodium thiocyanate). Antibody titers were too low to
measure the avidity of the antibody response for serum samples obtained from mice
immunized with PA released from the CPH:SA nanoparticles.
Lethal toxin in vitro cytotoxicity assay
The lethal toxin in vitro cytotoxicity assay was modified from a previously described
method6. The murine macrophage-like cell line RAW 264.7 obtained from ATCC
(Manassas, VA) was maintained in culture at 37°C in a 5% CO2 humidity using high
glucose DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-
inactivated FBS (Valley Biomedical, Winchester, VA), 100 IU/ml penicillin and 10 μg/ml
streptomycin (Mediatech, Herndon, VA). For the lethal toxin in vitro cytotoxicity assay,
RAW cells were transferred to a 96-well plate (100,000 cells per well) grown to
approximately 90% confluency in 100 μL medium over two days. Approximately 12 μL of
each treatment (PArel, PA-loaded nanoparticles, blank nanoparticle controls, medium only
control (negative control and 100% cell survival), native PA (positive control and 100% cell
death), LF (NIH Biodefense and Emerging Infections Research Resources Repository,
Manassas, VA) control, and cell lysis buffer) diluted in RAW medium were added to the
cells with 0.3 μg/mL LF for no more than 6 h. The amount of PA released from the
nanoparticles was calculated from the release curve in Figure 1. This assay was also utilized
to investigate antibody neutralization and shelf life (i.e., PA stability) of the PA-loaded
nanoparticles. For antibody neutralization assessment, individual serum samples (dilutions
ranging from 1:100 to 1:204800) from the different immunized mouse groups (described in
the in vitro release of PA for in vivo administration of the PArel section) were added to the
cells along with native PA (0.8 μg/mL) and LF (0.3 μg/mL). For antibody neutralization
assessment, the positive control was medium only (100% cell survival) and the negative
control was native PA (100% cell death). Samples were then allowed to incubate for up to 6
h, after which the CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT)
(Promega, Madison, WI) was used to determine cell viability. Optical density (OD) was
measured at 570 nm with a background (690 nm) subtraction as recommended by the
manufacturer’s protocol. Antibody neutralization was considered significant when measured
OD values fell below 50% of the positive control OD value. Data are presented as %
residual activity, as determined by Equation 1:
Eq. 1
Thermal stability of stored dry powder PA-loaded nanoparticle formulations
Bioactivity was tested with the lethal toxin in vitro cytotoxicity assay6 to determine the
ability of each formulation to preserve and release active PA. The thermal stability upon
storage was studied in formulations that included PA loaded into the nanoparticles (dry)
(labeled by polymer chemistry), PA dissolved in PBS buffer (labeled “PBS”), or PA
absorbed to alum (labeled “Alum”). All formulations were stored under desiccant at four
different temperatures, 40, 25, 4, and −20°C, for four months. Following storage, the
formulations were tested at prescribed times for their ability to preserve PA activity using
the lethal toxin in vitro cytotoxicity assay as described previously6. PA-loaded nanoparticle
bioactivity was evaluated at a concentration of 125 μg/mL for 6 h. This nanoparticle dose
was chosen because after 6 h of release (assay incubation time) the resultant PA
concentration was the same as that administered in the positive control (i.e. 0.8 μg/mL
native PA). It is important to note that nanoparticle formulations investigated in this study
were stored dry and were not added to aqueous buffers or medium until initiation of the
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cytotoxicity study, which lasted for 6 h. This is in contrast to the PA controls (i.e., PBS and
Alum), which were stored in solution to mimic the current storage strategy of the AVA
vaccine. The nanoparticle storage conditions in this study are distinctly different from those
in the studies investigating PA release, activity, structure, antigenicity, and immunogenicity
(Figures 1–4) in which the nanoparticles were incubated in an aqueous environment for
extended time periods (see previous methods) to enable sufficient release of the
encapsulated protein.
Statistical analysis
Statistical analyses performed using JMP® 7 (Cary, NC) and comparisons between
treatments were made with Tukey’s HSD (Honestly Significant Difference) to determine
statistical significance and p-values ≤ 0.05 were considered significant.
Results
Polymer and nanoparticle characterization
Consistent with previous work, polymer characterization by 1H NMR indicated that the
polymer molecular weights were within the desired ranges of 9,000–15,000 Da31, 33, 34. The
structure and composition of the polymers were also confirmed using NMR. SEM images
(data not shown) indicated that protein-loaded and blank nanoparticles resulted in similar
size (212 ± 43 nm) and morphology as previously reported16, 19, 27, 29, 35. Particle yield was
approximately 80% (recovery after filtration).
In vitro PA release and pH of nanoparticle degradation were dictated by chemistry
Release of PA and change in pH due to nanoparticle degradation were evaluated as a
function of time. As shown in Figure 1, polymer chemistry-dependent protein release
kinetics and buffer acidification were observed. Increasing the content of SA or CPTEG
relative to the CPH content resulted in a more rapid release of encapsulated PA (Figure 1A).
The 20:80 CPTEG:CPH particles provided the slowest PA release profile. This is consistent
with previously published studies demonstrating chemistry-dependent release profiles of
other proteins from polyanhydride nanoparticles22–25, 27, 28, 30, 36. The effect of the polymer
chemistry is also reflected in the pH profile of the degrading nanoparticles, as shown in
Figure 1B. The acidic monomers produced from the degradation of CPH:SA nanoparticles
have been shown to be water soluble25 and result in a greater decrease in pH (ΔpH = 2.5) as
compared to that of the CPTEG:CPH monomers (ΔpH = 0.6). In these experiments, an even
greater pH decrease (ΔpH = 5.0) was observed upon degradation of poly(lactic-co-glycolic
acid) (PLGA) nanoparticles (data not shown).
Protein activity and structural stability were preserved by amphiphilic CPTEG:CPH
nanoparticles
To evaluate PA stability upon release from nanoparticles, a detailed structural evaluation of
the PArel was performed (Figure 2). In this study, we analyzed the structural integrity of the
PArel that accumulated over 48 h. During this time, the protein was continually exposed to
the acidic microenvironments caused by the degradation of the polymers in an aqueous
environment. The CD spectrum for native PA revealed a minimum at approximately 208–
210 nm and a shoulder at 215–217 nm (Figure 2A). These findings were consistent with the
known CD spectra reported previously for the secondary structure of PA, and indicate that
PA consists mainly of a mixture of α-helices and β-sheets6, 37. Only the PA exposed to NFC
or released from 50:50 CPTEG:CPH nanoparticle formulations maintained the native
secondary structure (Figure 2A). PA released from all other formulations (20:80
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CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA) resulted in a significant increase in
molar ellipticity (Δε), indicating a loss of secondary structure.
Tertiary structure analysis, performed with fluorescence spectroscopy, revealed a red shift in
peak position for the PA released from all the nanoparticle formulations (Figure 2B). This
peak shift indicates exposure to a more polar environment indicative of protein unfolding6.
However, PA peak intensity was best preserved by encapsulation into and release from the
amphiphilic 50:50 CPTEG:CPH nanoparticles and to a lesser extent by encapsulation into
and release from 20:80 CPTEG:CPH nanoparticles. The nanoparticle fabrication conditions
appeared to have no detrimental effects on the tertiary structure of PA. In contrast, the
encapsulation of PA into and release from CPH:SA formulations resulted in a loss of tertiary
structure.
Following the structural evaluation, the relative antigenicity and bioactivity were assessed
for the PArel. The results of this study, which were used to identify lead candidate
formulations for stabilizing PA, are summarized in Figure 3. PA released from amphiphilic
50:50 CPTEG:CPH nanoparticles retained almost 80% of its antigenicity (Figure 3A) and
functional activity (Figure 3B). PA released from 20:80 CPTEG:CPH nanoparticles retained
52% of its activity but only 20% of its antigenicity, while CPH:SA-containing nanoparticles
preserved very little PA activity and antigenicity. Nanoparticle fabrication conditions had
little or no detrimental effect on the antigenicity or activity of PA (Figure 3).
In vivo immunization with the PA released from amphiphilic CPTEG:CPH nanoparticles
resulted in high titer, high avidity, neutralizing antibody
Upon completion of the structural, antigenicity and bioactivity studies, it was hypothesized
that the amphiphilic CPTEG:CPH nanoparticles would be the most viable candidates for
preserving the PArel, thus enabling a primed PA-specific antibody response when
administered in vivo. In order to determine the immunogenicity of the released protein,
separate groups of mice were immunized with alum adjuvanted PArel from the four
nanoparticle formulations. We hypothesized that if PA was degraded upon release from a
particular nanoparticle formulation, as seen for the PA released from the CPH:SA
nanoparticle chemistries (Figures 2 and 3), there would be a loss in the immunogenicity of
the PA. Antibody responses induced by the released protein were characterized in terms of
titer (Figure 4A), relative avidity (Figure 4B), and neutralizing antibody titer (Figure 4C).
The data indicated that the PA released from CPH:SA nanoparticles induced a weak
humoral response, while the PA released from the CPTEG:CPH nanoparticles or PA
exposed to the nanoparticle fabrication conditions resulted in the induction of high titer and
avid antibody responses that were statistically similar to those induced by native PA.
Overall, these data indicate that the immunogenicity of PA released from the amphiphilic
CPTEG:CPH nanoparticles was better preserved than that of PA released from CPH:SA
nanoparticles, as evidenced by the 4 log10 difference in antibody titer.
Shelf life stability of PA encapsulated into 50:50 CPTEG:CPH, 20:80 CPTEG:CPH, and
20:80 CPH:SA was superior to that of PA conjugated to alum
The ability of a PA-based vaccine to retain full immunogenicity upon storage is a major
concern. As a measure of PA stability, an in vitro cytotoxicity assay was employed to assess
the preservation of the biological activity of PA upon storage and immediate release from
polyanhydride nanoparticles. This study was also an assessment of the thermal stability of
the nanoparticles at various temperatures. During optimization of the cytotoxicity assay, we
determined that co-incubating 125 μg/mL of 0.8% PA-loaded nanoparticles for 6 h with
RAW 264.7 cells resulted in a concentration of PArel that was equivalent to that of the
positive control (i.e., 0.8μg/mL native PA). Because there was no statistical difference in the
Petersen et al. Page 7
Mol Pharm. Author manuscript; available in PMC 2013 April 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
amount of PA released between the different nanoparticle chemistries in the first 6 h (Figure
1), direct comparisons between the various polyanhydride formulations can be made. In this
study, the shelf life storage capabilities of i) PA loaded into polyanhydride nanoparticles
(dry), ii) PA in PBS buffer (pH 7.6), or iii) PA adsorbed to alum were investigated at
multiple time points following storage at 40, 25, 4, and −20°C. It is known that adjuvant
solutions containing alum have acidic bulk conditions (pH = 5.6)38, so a PBS buffer group
was included to investigate the effect of storage temperature at a neutral pH on the
bioactivity of PA.
In order to assess the preservation of the biological activity after dry storage for the desired
amount of time (1, 7, 14, 30, 60, and 120 days – only long term data are presented in this
manuscript), PA-loaded nanoparticles were directly applied to cultures of RAW 264.7 cells
at the initiation of a lethal toxin cytotoxicity assay. By employing these assay conditions,
any of the PArel was immediately available to bind to the host cell receptor, thus avoiding
any detrimental effects of accumulated acidic degradation products on the PArel. This is an
important difference between these studies and the stability studies described in Figures 2–4
in which the PArel was accumulated over several days in an aqueous environment before
assessing structural and antigenic integrity, and biological activity. After one week of
storage at 40°C, the biological activity of PA adsorbed to alum and PA stored in PBS buffer
was undetectable (Supplementary Figures 2A and B). Following two weeks and four months
of storage at 25°C, PA adsorbed to alum and PBS retained only half of its original
bioactivity respectively. After one month at 25°C, PA absorbed to alum lost all of its
bioactivity (Supplementary Figure 2A). After two months of storage at 40°C, PA
encapsulated into 20:80 and 50:50 CPTEG:CPH or 20:80 CPH:SA nanoparticles retained
from 60 to 90% of its biological activity (Supplementary Figure 1). After four months of
storage, PA encapsulated into 20:80 CPTEG:CPH and CPH:SA retained a significant
portion of its bioactivity (Figure 5). PA adsorbed to alum lost all its bioactivity after two
months of storage at all temperatures except −20°C (Figure 5 and Supplementary Figure
2A). When stored as a dry powder, 20:80 CPH:SA nanoparticles were capable of preserving
nearly 100% of the bioactivity of PA at all temperatures studied for 4 months. In contrast,
dry storage of 50:50 CPH:SA nanoparticles was ineffective at stabilizing PA under most of
the storage conditions tested. It is important to note that all nanoparticle chemistries were
successful in preserving PA bioactivity when stored at −20°C and could be viable vaccine
carriers when cold storage is available.
Discussion
Next-generation anthrax vaccines need to possess several attributes, including storage
stability and improved immunogenicity to reduce the need for multiple booster injections. In
this work, we have demonstrated that polyanhydride nanoparticle-based delivery systems
can stabilize PA and enhance the shelf life of PA-based vaccines. In particular, these studies
have shown that amphiphilic polyanhydride nanoparticles provide controlled antigen release
over several weeks, the release of immunogenic protein capable of inducing high titer,
neutralizing antibody, and extended shelf life storage at tropical and/or desert temperatures
(e.g., 40°C).
Long term or repeated antigen exposure (depot effect) is essential for the development of
immunological memory, which is a part of the rationale for the current immunization
regimen for the AVA vaccine (i.e., five immunizations with yearly boosters)3. In the event
of a bioterrorism attack, this protracted vaccination strategy may not be viable for treating a
naïve population. A need therefore exists for a vaccine capable of inducing levels of
neutralizing anti-PA antibody similar to that induced by the current immunization regimen,
but in a single dose, that will also improve patient compliance. The nanoparticle-based
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delivery system described in this work demonstrated sustained release kinetics for over two
months, dictated by polymer chemistry (Figure 1A), thereby offering an improved method
for delivery of biowarfare vaccines.
Although controlled release kinetics enable long-term antigen exposure, it is also essential
that the antigen remain stable during fabrication and long-term storage to maintain its
immunogenicity. Alum, an adjuvant that is currently approved for human use in the U.S., is
known to produce an acidic bulk-environment that can be detrimental for pH-sensitive
proteins38. While the adsorbed antigen would experience a less acidic microenvironment on
the surface of alum38, many pH-sensitive protein immunogens in the bulk would be
denatured and rendered ineffective by the acidic conditions (pH~5.6). PA is a highly labile
protein that is not only sensitive to acidic environments, but also to increased temperature -
an effect that is exacerbated as the conditions become more acidic6. In this work, we
demonstrated the superior PA stabilization capabilities of a nanoparticle-based delivery
system that preserved the biological activity of PA during fabrication, delivery, and storage/
thermal stability, thereby overcoming several of the problems associated with the use of
alum-based vaccines.
Because of the absence of water in the process, nanoparticle fabrication conditions (solvent
exposure, sonication, and vacuum drying) had no detectable effect on the structure,
antigenicity, or activity of PA. This demonstrates the utility of the polyanhydride
nanoparticle fabrication process for labile proteins, including PA, and is in agreement with
similar results for other proteins exposed to these conditions29. However, low pH and
elevated temperature have been reported to have more detrimental impact on the structural
stability and bioactivity of PA5–7, 37, 39. As shown in Figure 1B, the pH, due to
CPTEG:CPH nanoparticle erosion, only decreased to approximately 7.0 and was maintained
at that value for over 30 days. In contrast, the erosion of CPH:SA nanoparticles decreased
the pH to 5.2, which was similar to pH changes caused by alum. The acidic micro-
environment caused by degradation of the CPH:SA nanoparticles correlated with the losses
in structure (Figure 2), antigenicity and bioactivity (Figure 3) of PA released from these
nanoparticles. The PA released from CPH:SA nanoparticle formulations also failed to prime
an immune response capable of producing high titer, neutralizing serum antibody (Figure 4).
Detailed structural analysis demonstrated that significant alterations in the secondary and
tertiary structure of the PArel (Figure 2) were important determinants associated with the
loss in immunogenicity, bioactivity, and quality (i.e., avidity) of the antibody response
(Figure 4). Consistent with these results, it has been reported that thermally induced
ellipticity changes in PA occur in acidic environments5–7, 39. In addition, at low pH and high
temperature conditions, PA is structurally modified to a molten globular state6. As observed
in this work, this loss of structural integrity rendered PA biologically inactive and poorly
immunogenic.
Amphiphilic CPTEG:CPH nanoparticles, specifically 50:50 CPTEG:CPH, provided an
effective stabilizing environment for PA. While nearly 80% of PA antigenicity and activity
was preserved upon release from 50:50 CPTEG:CPH nanoparticles (Figure 3), less
antigenicity and activity were preserved (20% and 50%, respectively) upon release from
20:80 CPTEG:CPH nanoparticles (Figure 3). From the detailed structural analysis, it is
likely that the alterations in the secondary and tertiary structure of PA released from the
20:80 and 50:50 CPTEG:CPH nanoparticles (Figure 2C) may be responsible for the loss in
antigenicity and bioactivity (Figure 3). These alterations may result from the slight decrease
in pH at 37°C, consistent with what was reported by Jiang et al.6, which occurred as the
acidic degradation products built up over the duration of the in vitro stability study.
However, these polyanhydride chemistries did not prove to be detrimental to the
immunogenicity of PA. The total and neutralizing antibody titers as well as the antibody
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avidity for mice immunized with PA released from 20:80 or 50:50 CPTEG:CPH
nanoparticles were statistically indistinguishable from those induced by native PA (Figure
4). Thus, even in such “worst case” conditions (i.e., buildup of an acidic micro-environment
in a microcentrifuge tube), the amphiphilic polyanhydride chemistries were not deleterious
to PA.
One of the most difficult challenges to overcome in vaccine design and development is long-
term storage and maintenance of bioactivity. This is an immediate concern in developing
countries with limited infrastructure for cold storage. In this work, we tested the thermal
stability of PA-loaded nanoparticles, PA adsorbed to alum, and PA in PBS for four months
over a 60-degree temperature range (−20 to 40°C) while under dry storage. The changes
observed in PA stored with alum are hypothesized to be a result of the acidic pH
environment combined with the storage temperature. In contrast, PA stored in PBS buffer at
a neutral pH is only likely to be affected by storage temperature. After two months of dry
storage, all polyanhydride chemistries, except for 50:50 CPH:SA, outperformed the alum
group in preserving the stability of PA at 40, 25, and 4°C (Supplementary Figure 1). After
four months of dry storage, PA released from 20:80 CPTEG:CPH and CPH:SA
nanoparticles retained its bioactivity (Figure 5). In these studies, it is important to note that
dry formulations were evaluated while the studies described in Figures 2–4 tested PA-loaded
nanoparticles that were incubated in an aqueous environment (to obtain the PArel). The dry
storage conditions largely eliminate the build-up of acidic degradation products. This may
explain why the 20:80 CPH:SA nanoparticles preserved PA bioactivity under these
conditions.
Furthermore, these results indicate that the thermal properties of the copolymers, mainly the
glass transition temperature (Tg), may play an integral role in particle shelf life over
prolonged periods at elevated temperatures. Nanoparticles with Tgs close to or lower than
the storage temperature may lose their particle structure due to their transition to a rubbery
phase. The Tg values of 20:80 CPTEG:CPH, 50:50 CPTEG:CPH, 20:80 CPH:SA, and 50:50
CPH:SA have been reported to be 18, 8, 50, and 11°C, respectively31, 40, 41. This may
explain why the polymers with the two lowest Tgs (i.e., 50:50 CPTEG:CPH and 50:50
CPH:SA) are unable to release bioactive PA upon extended storage at 25 or 40°C. In
addition, the hydrophobic 50:50 CPH:SA chemistry may induce non-covalent hydrophobic
interactions with PA that may lead to aggregation and loss of bioactivity. The 20:80
CPTEG:CPH and 20:80 CPH:SA nanoparticles revealed similar abilities to preserve PA at
40 and 25°C for 4 months, demonstrating enhanced nanoparticle thermal stability and
subsequent protein stabilization similar to lyophilized PA stored with stabilizers after only
one month6. While protein released from the 20:80 CPH:SA nanoparticles was not able to
induce a robust antibody response following immunization, these formulations provided a
suitable dry storage formulation at elevated temperatures. In contrast, the amphiphilic 20:80
CPTEG:CPH nanoparticles were able to induce robust antibody responses following
immunization and provide for the preservation of a labile protein during long-term storage at
tropical temperatures. The preliminary studies described herein have demonstrated a novel
strategy for the design and development of a next-generation anthrax vaccine formulation
with long-term stable storage capabilities.
Conclusions
Together, the studies reported herein demonstrate the potential use of a polyanhydride
nanoparticle platform in next-generation vaccines employing recombinant proteins. These
polyanhydride nanoparticles provide the ability to control PA antigen release, which would
provide an in vivo antigen depot capable of long-term antigen presentation. Additionally,
amphiphilic polyanhydride nanoparticles demonstrated superior thermal shelf life stability
Petersen et al. Page 10
Mol Pharm. Author manuscript; available in PMC 2013 April 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and the ability to withstand “worst case” conditions, thus making them capable of preserving
PA bioactivity upon fabrication and storage at elevated temperatures. Of the four
formulations tested, the amphiphilic 20:80 CPTEG:CPH nanoparticles demonstrated the best
combination of characteristics to facilitate the stabilization of labile proteins, such as PA,
making them excellent candidates for next-generation single-dose anthrax vaccines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
PA was released from polyanhydride nanoparticles in a chemistry dependent manner. A)
Release of PA from polyanhydride nanoparticles over 60 days and B) the change in pH of
PBS buffer (pH 7.6, 0.1 M) from nanoparticle degradation over 30 days. Error bars represent
standard deviation of three replicates performed in three independent experiments.
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Figure 2.
50:50 CPTEG:CPH best preserved the structural integrity of PA while CPH:SA nanoparticle
chemistries cause a loss in secondary and tertiary structural integrity. A) Secondary structure
as measured by circular dichroism (CD) and B) tertiary structure as measured by
fluorescence spectroscopy after two days of release from polyanhydride nanoparticles.
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Figure 3.
CPTEG:CPH nanoparticle chemistries released biologically active and antigenic PA. A)
Residual antigenicity and B) residual activity of PA after two days of release from
polyanhydride nanoparticles. The direct ELISA was performed with 0.5 μg/mL PArel from
the nanoparticles. The biological assay was performed by incubating 6.4 μg/mL PArel from
polyanhydride nanoparticles with 0.3 μg/mL LF with RAW cells for 6 h. Error bars
represent standard deviation of 3 replicates. Treatments with different letters are
significantly different from one another at p < 0.05.
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Figure 4.
Mice immunized with PA released from 50:50 and 20:80 CPTEG:CPH, adjuvanted with
alum, developed the highest antibody titers, the most avid antibody response, and highest
neutralizing antibody titers. A) Antibody titers, B) antibody avidity (ND (not determined)
for 20:80 and 50:50 CPH:SA because antibody titers were too low), and C) antibody
neutralization titers of serum samples from immunized mice. Data is presented as the mean
± SEM of three replicates. All serum samples were evaluated individually. Treatments with
different letters are significantly different from one another at p < 0.0001.
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Figure 5.
Dry powder formulations of PA-loaded 20:80 CPTEG:CPH and CPH:SA polyanhydride
nanoparticles were capable of preserving the activity of PA for four months when stored at
40, 25, 4, and −20°C. The biological assay was performed by incubating 125 μg/mL
nanoparticles with 0.3 μg/mL LF with RAW cells for 6 h. Error bars represent standard
deviation of 3 replicates. Treatments with different letters are significantly different from
one another at p < 0.05.
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